OncoCyte (OCX) Reports Q3 Loss, Lags Revenue Estimates

OncoCyte (OCX) delivered earnings and revenue surprises of -57.14% and -69.25%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Leave a comment

Your email address will not be published. Required fields are marked *